United States - English - NLM (National Library of Medicine)

nucare pharmaceuticals,inc. - enalapril maleate (unii: 9o25354epj) (enalaprilat anhydrous - unii:q508q118jm), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - enalapril maleate 10 mg - enalapril maleate and hydrochlorothiazide is indicated for the treatment of hypertension. this fixed dose combination is not indicated for initial treatment (see dosage and administration ). in using enalapril maleate and hydrochlorothiazide, consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that enalapril does not have a similar risk (see warnings ). in considering use of enalapril maleate and hydrochlorothiazide, it should be noted that black patients receiving ace inhibitors have been reported to have a higher incidence of angioedema compared to non-blacks (see warnings, head and neck angioedema ). enalapril maleate and hydrochlorothiazide is contraindicated in patients who are hypersensitive to any component of this product and in patients with a history of an

Australia - English - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - enalapril maleate, quantity: 20 mg - tablet, uncoated - excipient ingredients: hypromellose; lactose monohydrate; iron oxide red; maleic acid; zinc stearate; iron oxide yellow; maize starch - hypertension. enalapril generic health is indicated in the treatment of: all grades of essential hypertension; renovascular hypertension. congestive heart failure. enalapril generic health is indicated in the treatment of all degrees of symptomatic heart failure. in such patients it is recommended that enalapril be administered together with a diuretic. left ventricular dysfunction. all degrees of left ventricular dysfunction where the left ventricular ejection fraction is less than 35%, irrespective of the presence or severity of obvious symptoms of heart failure.

Australia - English - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - enalapril maleate, quantity: 10 mg - tablet, uncoated - excipient ingredients: hypromellose; maleic acid; iron oxide red; zinc stearate; maize starch; lactose monohydrate - hypertension. enalapril generic health is indicated in the treatment of: all grades of essential hypertension; renovascular hypertension. congestive heart failure. enalapril generic health is indicated in the treatment of all degrees of symptomatic heart failure. in such patients it is recommended that enalapril be administered together with a diuretic. left ventricular dysfunction. all degrees of left ventricular dysfunction where the left ventricular ejection fraction is less than 35%, irrespective of the presence or severity of obvious symptoms of heart failure.

Australia - English - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - enalapril maleate, quantity: 5 mg - tablet, uncoated - excipient ingredients: maleic acid; zinc stearate; maize starch; hypromellose; lactose monohydrate - hypertension. enalapril generic health is indicated in the treatment of: all grades of essential hypertension; renovascular hypertension. congestive heart failure. enalapril generic health is indicated in the treatment of all degrees of symptomatic heart failure. in such patients it is recommended that enalapril be administered together with a diuretic. left ventricular dysfunction. all degrees of left ventricular dysfunction where the left ventricular ejection fraction is less than 35%, irrespective of the presence or severity of obvious symptoms of heart failure.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - enalapril maleate, quantity: 2.5 mg - tablet, uncoated - excipient ingredients: sodium bicarbonate; lactose monohydrate; pregelatinised maize starch; magnesium stearate; maize starch - hypertension. all grades of essential hypertension; renovascular hypertension. congestive heart failure. treatment of all degrees of symptomatic heart failure. in such patients it is recommended that enalapril maleate be administered together with a diuretic. left ventricular dysfunction. all degrees of left ventricular dysfunction where the left ventricular ejection fraction is less than 35%, irrespective of the presence or severity of obvious symptoms of heart failure.

New Zealand - English - Medsafe (Medicines Safety Authority)

apotex nz ltd - cilazapril monohydrate 1.0425mg equivalent to 1 mg cilazapril - film coated tablet - 1 mg - active: cilazapril monohydrate 1.0425mg equivalent to 1 mg cilazapril excipient: hyprolose hypromellose iron oxide yellow macrogol 8000 maize starch microcrystalline cellulose purified water sodium stearyl fumarate titanium dioxide - apo-cilazapril is indicated in the treatment of all grades of essential hypertension and renovascular hypertension.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

zentiva pharma uk ltd - enalapril maleate - oral tablet - 20mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

alliance healthcare (distribution) ltd - enalapril maleate - oral tablet - 20mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - enalapril maleate - oral tablet - 20mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

accord-uk ltd - enalapril maleate - oral tablet - 20mg